Impact of Sodium‐Glucose Cotransporter‐2 Inhibitors on Quality of Life and Patient‐Reported Outcomes in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta‐Analysis
- 31 March 2026
- journal article
- review article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (6) , 4559-4572
Abstract
Background: Sodium‐glucose cotransporter‐2 (SGLT2) inhibitors improve glycemic and cardiovascular outcomes in type 2 diabetes mellitus (T2DM). However, their impact on quality of life (QoL) and patient‐reported outcomes (PROs) has not been systematically evaluated. We conducted a systematic review and meta‐analysis to assess the effect of SGLT2 inhibitors on QoL in patients with T2DM. Methods: MEDLINE, Embase, Scopus, Cochrane and ClinicalTrials.gov were searched until 18 August 2025 for randomised controlled trials and post hoc analyses of SGLT2 inhibitors reporting validated QoL or PRO outcomes in adults with T2DM. A random‐effects model was used to estimate mean differences (MD) or odds ratios (OR) with 95% CIs. Subgroup analyses compared SGLT2 inhibitors with placebo and active comparators. Risk of bias was assessed using the Cochrane RoB‐2 tool. Results: Ten studies including 5294 patients (SGLT2i: 2807; control: 2487) were included. SGLT2 inhibitors significantly improved: EQ‐5D Index score versus placebo (MD: 0.04, p = 0.008), DTR‐QoL against active comparators (MD: 6.99; p = 0.0006), DTSQ compared to active comparators (MD: 0.54; p = 0.006) and IWQoL (MD: 1.44; p = 0.005) versus placebo. Improvements were also observed in SHIELD WQ‐9 overall QoL (OR: 2.11; p = 0.005), emotional health (OR: 2.16; p = 0.006), self‐esteem (OR: 2.26; p = 0.006) and work performance (OR: 1.99; p = 0.04) compared with placebo. Conclusion: Randomised evidence suggests SGLT2 inhibitors enhance EQ‐5D Index score, diabetes‐specific QoL and several PROs in T2DM, particularly in physical, emotional and treatment satisfaction domains, supporting their earlier use in this population.Keywords
This publication has 36 references indexed in Scilit:
- Sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes and myocardial infarction undergoing percutaneous coronary intervention: A systematic review and meta-analysisAmerican Journal of Preventive Cardiology, 2024
- SGLT2 Inhibitors, Functional Capacity, and Quality of Life in Patients With Heart FailureJAMA Network Open, 2024
- The Ceiling Effects of EQ-5D-3L and 5L in General Population Health Surveys: A Systematic Review and Meta-AnalysisValue in Health, 2024
- SGLT inhibitors on weight and body mass: A meta‐analysis of 116 randomized‐controlled trialsObesity, 2021
- Introduction to Meta‐Analysis2021
- CANadian CAnagliflozin REgistry: Patient-Reported Outcomes of Canagliflozin in the Treatment of Type 2 Diabetes Mellitus in Canadian Clinical PracticeCanadian Journal of Diabetes, 2019
- Cochrane Handbook for Systematic Reviews of Interventions2019
- Lifestyle Change and Mobility in Obese Adults with Type 2 DiabetesNew England Journal of Medicine, 2012
- How Valid and Responsive Are Generic Health Status Measures, such as EQ-5D and SF-36, in Schizophrenia? A Systematic ReviewValue in Health, 2011
- Validity, reliability, and responsiveness of the EQ-5D in inflammatory bowel disease in GermanyInflammatory Bowel Diseases, 2010